Related references
Note: Only part of the references are listed.Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
Brent A. McLean et al.
ENDOCRINE REVIEWS (2021)
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity
D. Weghuber et al.
PEDIATRIC OBESITY (2020)
Effect of liraglutide on food consumption, appetite sensations and eating behaviours in overweight people with type 1 diabetes
Marie-Christine Dube et al.
DIABETES OBESITY & METABOLISM (2020)
Obesity Treatment Among Adolescents A Review of Current Evidence and Future Directions
Michelle I. Cardel et al.
JAMA PEDIATRICS (2020)
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Aaron S. Kelly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
Robert F. Kushner et al.
OBESITY (2020)
Improving Adherence to Weight-Loss Medication (Liraglutide 3.0 mg) Using Mobile Phone Text Messaging and Healthcare Professional Support
Ang Li et al.
OBESITY (2020)
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis
Gilles R. Dagenais et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Liraglutide for Adolescents with Obesity
Aaron S. Kelly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Measures of adherence as predictors of early and total weight loss with intensive behavioral therapy for obesity combined with liraglutide 3.0 mg
Jena S. Tronieri et al.
BEHAVIOUR RESEARCH AND THERAPY (2020)
GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials
Chuqing Cao et al.
ENDOCRINE (2020)
Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis
Lana C. Pinto et al.
SCIENTIFIC REPORTS (2019)
Liraglutide in Children and Adolescents with Type 2 Diabetes
William V. Tamborlane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The epidemiological burden of obesity in childhood: a worldwide epidemic requiring urgent action
Mariachiara Di Cesare et al.
BMC MEDICINE (2019)
Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet
Simon Birk Kjaer Jensen et al.
BMJ OPEN (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study
Maria Letizia Petroni et al.
ENDOCRINOLOGY DIABETES & METABOLISM (2019)
Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins
Yukiko Hasegawa et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Incretin-Based Therapies and the Short-term Risk of Pancreatic Cancer: Results From Two Retrospective Cohort Studies
Mathieu Boniol et al.
DIABETES CARE (2018)
Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years
Thomas Danne et al.
JOURNAL OF PEDIATRICS (2017)
The effects of GLP-1 analogues on pre-diabetes of the children
Qing-Xia Zhou et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2017)
Recombinant Incretin-Secreting Microbe Improves Metabolic Dysfunction in High-Fat Diet Fed Rodents
Paul M. Ryan et al.
SCIENTIFIC REPORTS (2017)
Effectiveness of educational and lifestyle interventions to prevent paediatric obesity: systematic review and meta-analyses of randomized and non-randomized controlled trials
D. Gori et al.
OBESITY SCIENCE & PRACTICE (2017)
Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials
Matteo Monami et al.
DIABETES OBESITY & METABOLISM (2017)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Liraglutide's Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Pediatric Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
David J. Klein et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2014)
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
John B. Buse et al.
LANCET (2013)
The Effect of Glucagon-Like Peptide-1 Receptor Agonist Therapy on Body Mass Index in Adolescents With Severe Obesity A Randomized, Placebo-Controlled, Clinical Trial
Aaron S. Kelly et al.
JAMA PEDIATRICS (2013)
Exenatide as a Weight-Loss Therapy in Extreme Pediatric Obesity: A Randomized, Controlled Pilot Study
Aaron S. Kelly et al.
OBESITY (2012)
The nuts and bolts of PROSPERO: an international prospective register of systematic reviews
Alison Booth et al.
SYSTEMATIC REVIEWS (2012)
Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
Lotte Bjerre Knudsen et al.
ENDOCRINOLOGY (2010)
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
Michaela Diamant et al.
LANCET (2010)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
Alessandro Liberati et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Establishing a standard definition for child overweight and obesity worldwide: international survey
TJ Cole et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
Share Paper
